Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Phase III Study of Remimazolam in Patients Undergoing Bronchoscopy
NCT02296892 · View on ClinicalTrials.gov ↗
Study Summary
A prospective, double-blind, randomized, placebo and active controlled, multi-center, parallel group study comparing remimazolam to placebo, with an additional open label arm for midazolam, in patients undergoing a bronchoscopy.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Midazolam
- DRUG Remimazolam
Study Locations (14)
North Carolina
- Unc Division of Pulmonary and Critical Care — Chapel Hill
- Duke University — Durham
- Pinehurst Medical Clinic — Pinehurst
- Wake Forest Baptist Health — Winston-Salem
Florida
- Pab Clinical Research — Brandon
- Sun City Office — Sun City Center
South Carolina
- Medical University of South Carolina — Charleston
- S. Carolina Pharmaceutical Research — Spartanburg
Virginia
- Pulmonary Associates of Richmond — Richmond
- Virginia Commonwealth University — Richmond
Indiana
- Laporte County Institute For Clinical Research — Michigan City
Maryland
- The Johns Hopkins Center for Interventional and Pulmonary Care — Baltimore
Missouri
- Washington University School of Medicine/Barnes-Jewish Hospital — St Louis
Washington
- Multicare Institute For Research & Innovation — Tacoma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 446 participants |
| Start Date | 2015-04 |
| Est. Completion | 2017-03-13 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02296892
The ClinicalTrials.gov registry entry for NCT02296892 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 446 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Paion UK, which has 3 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Bronchoscopy appearing as the primary indexed condition, and to 3 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT02296892 reports 14 study locations spanning 8 distinct geographic areas — top geographies include North Carolina, Florida, South Carolina. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT02296892 about?
NCT02296892 is a clinical study titled "A Phase III Study of Remimazolam in Patients Undergoing Bronchoscopy". A prospective, double-blind, randomized, placebo and active controlled, multi-center, parallel group study comparing remimazolam to placebo, with an additional open label arm for midazolam, in patients undergoing a bronchoscopy.
What is the current status of trial NCT02296892?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 446 participants. The study started on 2015-04. Estimated completion is 2017-03-13.
What conditions does trial NCT02296892 study?
This clinical trial studies the following conditions: Bronchoscopy. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT02296892?
The interventions under investigation include: Placebo (DRUG), Midazolam (DRUG), Remimazolam (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT02296892?
This trial is sponsored by Paion UK, which has 3 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT02296892 being conducted?
This trial has 14 study locations across Florida, Indiana, Maryland, Missouri, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.